Download or read book Biology and Treatment of Leukemia and Bone Marrow Neoplasms written by Vinod Pullarkat and published by Springer Nature. This book was released on 2021-10-09 with total page 200 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.
Download or read book The Biology and Treatment of Myeloid Leukaemias written by Geoffrey Brown and published by MDPI. This book was released on 2018-04-17 with total page 199 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a printed edition of the Special Issue "The Biology and Treatment of Myeloid Leukaemias" that was published in IJMS
Download or read book Biology and Management of Multiple Myeloma written by James R. Berenson and published by Springer Science & Business Media. This book was released on 2004-05-14 with total page 375 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.
Download or read book Advances in Biology and Therapy of Multiple Myeloma written by Nikhil C. Munshi and published by Springer Science & Business Media. This book was released on 2012-11-15 with total page 322 pages. Available in PDF, EPUB and Kindle. Book excerpt: Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Download or read book Adult Acute Lymphocytic Leukemia written by Anjali S. Advani and published by Springer Science & Business Media. This book was released on 2010-11-18 with total page 396 pages. Available in PDF, EPUB and Kindle. Book excerpt: The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population.
Download or read book Myeloproliferative Neoplasms written by Srdan Verstovsek and published by Springer Science & Business Media. This book was released on 2010-10-17 with total page 233 pages. Available in PDF, EPUB and Kindle. Book excerpt: This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.
Download or read book Role of Cancer Stem Cells in Cancer Biology and Therapy written by Thomas Dittmar and published by CRC Press. This book was released on 2016-04-19 with total page 330 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book summarizes the latest findings about the role of cancer stem cells (CSCs) in cancer biology and how this knowledge could be used for novel anticancer therapies. It provides an overview of CSCs in selected malignancies with particular emphasis on hematopoietic neoplasias. It then reviews the role of CSCs in metastasis formation and initiat
Download or read book Advances in Biology and Therapy of Multiple Myeloma written by Nikhil C. Munshi and published by Springer Science & Business Media. This book was released on 2012-12-09 with total page 291 pages. Available in PDF, EPUB and Kindle. Book excerpt: Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Download or read book Biology and Therapy of Acute Leukemia written by L.O. Baker and published by Springer. This book was released on 1985-05-31 with total page 259 pages. Available in PDF, EPUB and Kindle. Book excerpt: This year notes two major changes in the annual Detroit Cancer Symposium. The first is our intention of selecting top ics of broad interest to the cancer community and examining the subject from both a basic laboratory and clinical viewpoint. In this way, the importance of both elements of cancer research are noted and the interplay between them emphasized. Further, we believe that Symposia such as this act to stimulate the basic scientist and clinician to continue their studies with the know ledge of the impact that each has upon the other and the nec essary cooperation required to solve the cancer problem. The second change is the publication of this Symposium. The pre vious sixteen were not committed to manuscript form. Given the change in format and intent of the series, we believe that this and subsequent volumes will make important contributions to the cancer literature. The topic of "Biology and Therapy of Acute Leukemia" was chosen for the first Symposium because of its historical signif icance in cancer chemotherapy. The therapeutic rationale for human leukemia is the result of understanding the basic tumor biology largely derived from transplantable leukemias in exper imental animals. It is through these models, as discussed by Dr. Fred Valeriote, that we learned the cellular kinetics of leukemia, the antileukemic effects of new agents and the ef fect of growth perturbation by various chemotherapeutic agents and their combinations.
Download or read book Myeloproliferative Neoplasms Biology and Treatment written by and published by Frontiers Media SA. This book was released on 2024-04-10 with total page 124 pages. Available in PDF, EPUB and Kindle. Book excerpt: Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) - including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PM) - are clonal stem cell disorders characterized by acquired activating mutations which result in an excessive production of red blood cells, platelets, and neutrophils. Recent advances in the understanding of the molecular biology and genomics of MPNs have led to the development of novel targeted treatment approaches; however, the high rate of life-threatening vascular events and the high risk of disease progression with myelofibrotic and leukemic transformation continue to present challenges in the management of MPNs. Thereby, there remains a need for novel treatment strategies. Recently, research has revealed a role for clonal hematopoiesis, driver mutations and inflammation in thrombosis risk, which may provide a basis for novel thrombosis-prevention strategies.
Download or read book Cellular and Molecular Aspects of Myeloproliferative Neoplasms Part B written by and published by Academic Press. This book was released on 2022-02-11 with total page 242 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B, Volume 366 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. Sections cover Genetic and Sex predisposition to MPN, Transcriptional configurations of Myeloproliferative Neoplasms, Inhibitors and therapeutic targets of MPN, Mutational landscape of blast-phase myeloproliferative neoplasm (MPN-BP) and antecedent MPN, and Lessons from Mouse model of MPN, Lab tests for MPN. - Publishes only invited review articles on selected topics - Authored by established and active cell and molecular biologists from international sources - Offers a wide range of perspectives on specific subjects
Download or read book Chronic Leukemias and Lymphomas written by Gary J. Schiller and published by Springer Science & Business Media. This book was released on 2002-10-16 with total page 325 pages. Available in PDF, EPUB and Kindle. Book excerpt: In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.
Download or read book Hematopoietic Cell Transplantation in Children with Cancer written by Franklin O. Smith and published by Springer Science & Business Media. This book was released on 2013-11-26 with total page 362 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a comprehensive and up-to-date compendium on all aspects of blood and marrow transplantation in children. After an introductory chapter describing the history of pediatric blood and marrow transplantation, subsequent chapters discuss pediatric-specific aspects of transplantation, including stem cell sources suitable for transplantation, preparative regimens, graft-versus-host disease, complications related to transplantation, and late effects. The role of blood and marrow transplantation in various specific pediatric diseases is then examined, and the closing chapter considers future directions. The authors are all internationally recognized experts and offer a largely evidence-based consensus on etiology, biology, and treatment. This handbook has far-reaching applicability to the clinical diagnosis and management of pediatric diseases that are treatable with blood and marrow transplantation and will prove invaluable to specialists, generalists, and trainees alike.
Download or read book Hematology written by Margarita Guenova and published by BoD – Books on Demand. This book was released on 2018-06-27 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hematology has constantly been advancing in parallel with technological developments that have expanded our understanding of the phenotypic, genetic, and molecular complexity and extreme clinical and biological heterogeneity of blood diseases. This has in turn allowed for developing more effective and less toxic alternative therapeutic approaches directed against critical molecular pathways. The continuous and rather extensive influx of new information regarding the key features and underlying mechanisms as well as treatment options in hematology requires a frequent update of this topic. The primary objective of this book is to provide the specialists involved in the clinical management and experimental research in hematological diseases with comprehensive and concise information on some important theoretical and practical developments in the biology, clinical assessment, and treatment of patients, as well as on some molecular and pathogenetic mechanisms and the respective translation into novel therapies.
Download or read book Biological Mechanisms of Minimal Residual Disease and Systemic Cancer written by Julio A. Aguirre-Ghiso and published by Springer. This book was released on 2018-11-08 with total page 165 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book focuses on the biological mechanisms of minimal residual disease (MRD) and recurrence. It integrates this biology in solid cancers and in hematological malignancies. It reports also on technological advancements for monitoring MRD, derived from mechanistic insights. Chapters in solid and hematological malignancies address stem cell biology, genetics, epigenetics and micro-environmental regulation of dormant MRD. Novel insight into technologies for molecular phenotyping of MRD and monitoring of CTCs, DTCs and cell free RNA and DNA are also addressed extensively. Five chapters explore the above concepts in solid cancers such as prostate, breast, melanoma, head and neck and esophageal. Two chapters also explore the basic mechanisms of vascular biology targeting and epigenetic mechanisms regulating pluripotency programs during dormancy. Similar biology is explored in hematological malignancies such as T-ALL, CML, AML and multiple myeloma in additional four chapters. This book is edited and prefaced by Dr. Julio Aguirre-Ghiso, an expert in dormancy and recurrence. The chapters are written by world-recognized experts Drs. Ravi Bahtia, Samir Parekh, Russel Taichman, Monica Guzman, David Hoon, Denis Schewe, Irmela Jeremias, Cyrus Ghajar, Maria Soledad Sosa and Nicholas Stoecklein. The topic of this book is of particular interest to both basic cancer cell biologists and physician scientists that are working to provide a more integrated view of the biology of MRD and to those interested in working on or learning about this paradigm. The integrated and cross-disciplinary focus of the book from biology to medicine seeks to help bridge gaps to improve cancer care and prevent recurrences.
Download or read book Hematopoietic Growth Factors in Oncology written by Gary Lyman and published by Springer Science & Business Media. This book was released on 2010-11-05 with total page 431 pages. Available in PDF, EPUB and Kindle. Book excerpt: Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient’s well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of potentially curative cancer treatment. Despite the increasing complexity of modern cancer treatment, it is the obligation of the oncologist as well as the entire cancer care team to be certain that cancer patients receive the optimal supportive care available for their disease and its treatment. Among the most serious and potentially life threatening toxicities of cancer treatment are the hematologic toxicities accompanying myelosuppression including anemia and associated asthenia and fatigue, neutropenia and fever associated with infection in the immunocompromised patient and thrombocytopenia and accompanying risk of bleeding. Special supportive care needs arise in the very elderly care patient that may tax the ability of even the most skilled clinician. Despite the considerable progress that has been made with more effective and safer treatment strategies, myelosuppressive chemotherapy will remain the mainstay of systemic treatment for cancer for the foreseeable future. While considerable progress has occurred, better methods and broader application of supportive care measures are needed to reduce the symptomatic effects of cancer and the associated toxicities associated with cancer treatment. No area of cancer supportive care better illustrates the progress that has resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factors. This volume will review and integrate the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. The current clinical utilization of these agents is based on numerous randomized controlled trials and meta-analyses along with evidence-based clinical practice guidelines developed by professional societies guiding their appropriate and cost-effective use in clinical care.
Download or read book The Biological Basis of Cancer written by Robert G. McKinnell and published by Cambridge University Press. This book was released on 1998-03-13 with total page 404 pages. Available in PDF, EPUB and Kindle. Book excerpt: A new textbook, designed for undergraduates taking a cancer course, covering everything from the molecular to the clinical aspects of the subject.
